NewsBenzingaGeron Q2 2026 Earnings Call: Complete Transcript Geron Q2 2026 Earnings Call: Complete Transcript Benzinga 2026.10.08 08:19 (GMT+0) Open on Benzinga Other news BTIG Reiterates Buy on Nomad Foods, Maintains $15 Price Target Goldman Sachs Upgrades Palantir Technologies to Buy, Announces $230 Price Target Needham Reiterates Buy on Levi Strauss, Maintains $28 Price Target Applied Digital CEO Says AI Demand Is Near Maximum Goldman Sachs Downgrades Tyler Technologies to Neutral, Lowers Price Target to $345 Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
